Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Cerilliant
McKesson
Baxter
Johnson and Johnson
Covington
UBS
Colorcon

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYRBETRIQ

« Back to Dashboard

Clinical Trials for Myrbetriq

Trial ID Title Status Sponsor Phase Summary
NCT00410514 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed Astellas Pharma Inc Phase 2 This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00688688 Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
NCT00689104 Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
NCT01340027 A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder Completed Astellas Pharma Europe B.V. Phase 2 The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
NCT01638000 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. Completed Astellas Pharma Europe Ltd. Phase 3 The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Myrbetriq

Condition Name

Condition Name for Myrbetriq
Intervention Trials
Overactive Bladder 11
Urinary Bladder, Overactive 5
Urinary Bladder Overactive 4
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Myrbetriq
Intervention Trials
Urinary Bladder, Overactive 18
Urologic Diseases 6
Urinary Bladder Diseases 6
Urinary Incontinence 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Myrbetriq

Trials by Country

Trials by Country for Myrbetriq
Location Trials
United States 189
Canada 37
Denmark 9
Germany 9
United Kingdom 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Myrbetriq
Location Trials
New York 9
California 8
Massachusetts 8
Florida 8
Virginia 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Myrbetriq

Clinical Trial Phase

Clinical Trial Phase for Myrbetriq
Clinical Trial Phase Trials
Phase 4 8
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Myrbetriq
Clinical Trial Phase Trials
Completed 14
Recruiting 12
Not yet recruiting 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Myrbetriq

Sponsor Name

Sponsor Name for Myrbetriq
Sponsor Trials
Astellas Pharma Europe B.V. 7
Astellas Pharma Inc 6
Astellas Scientific & Medical Affairs, Inc. 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Myrbetriq
Sponsor Trials
Industry 23
Other 21
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Deloitte
Accenture
Moodys
Daiichi Sankyo
Fish and Richardson
Citi
Federal Trade Commission
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.